Biotechnology - Neurological, Rare diseases


Current filters:

NeurologicalRare diseases

Popular Filters

Orphan status for Alexion's Solaris


US drugmaker Alexion Pharmaceuticals (Nasdaq: ALXN) says that Soliris (eculizumab), the company's first-in-class…

Alexion PharmaceuticalsBiotechnologyEuropeNeurologicalPharmaceuticalRare diseasesRegulationSolaris

Repligen in $70 million deal with Pfizer for SMA program


USA-based Repligen (Nasdaq: RGEN) saw its share jump 5.6% to $6.63, after the company revealed it has…

BiotechnologyLicensingNeurologicalPfizerPharmaceuticalRare diseasesRepligenRG3039

Makers of Kynamro and Fanaptum to appeal negative CHMP opinions


French drug major Sanofi's (Euronext: SAN) subsidiary Genzyme and US partner Isis Pharmaceuticals (Nasdaq:…

BiotechnologyEuropeFanaptFanaptumGenzymeIsis PharmaceuticalsKynamroNeurologicalPharmaceuticalRare diseasesRegulationSanofiVanda Pharmaceuticals

Germany's IQWiG finds in favor of Yervoy but not Benlysta or Fampyra


The German Institute for Quality and Efficiency in Health Care (IQWiG) in the past few days issued a…

BenlystaBiogen IdecBiotechnologyBristol-Myers SquibbEuropeFampyraGlaxoSmithKlineNeurologicalOncologyPharmaceuticalPricingRare diseasesRegulationYervoy

Drug shortages spur developments in neurometabolic treatments


A prolonged gap in the neurology market following the shutdown of a Genzyme production facility is tempting…

BiotechnologyMarkets & MarketingNeurologicalPharmaceuticalRare diseasesResearch

Back to top